Vital Signs The Analyst's Perspective - August 2015 Issue

Share this:
     
Published: 28 Sep 2015

This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

  1.  

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..